Deltex Medical Group plc
Deltex Medical Group plc (DTXMF) Stock Competitors & Peer Comparison
See (DTXMF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DTXMF | $0.10 | +0.00% | 180.6M | -9.52 | -$0.01 | N/A |
| SEMHF | $40.65 | +1.10% | 45.5B | 18.48 | $2.20 | +2.95% |
| RSMDF | $17.93 | +0.00% | 43.3B | 28.67 | $1.04 | +1.29% |
| FUJIY | $10.53 | +1.64% | 25.4B | 15.04 | $0.70 | +1.85% |
| RYLPF | $25.44 | -4.81% | 24.2B | 21.93 | $1.16 | +3.72% |
| FUJIF | $20.00 | +0.00% | 23.9B | 14.18 | $1.41 | +2.28% |
| SMMNY | $19.95 | -1.77% | 22.3B | 18.15 | $1.10 | +2.98% |
| SONVF | $275.60 | +2.84% | 15.9B | 23.43 | $11.44 | +1.97% |
| SONVY | $52.06 | -1.49% | 15.5B | 22.79 | $2.29 | +2.03% |
| CLPBY | $6.01 | -3.06% | 13.5B | 40.07 | $0.15 | +5.96% |
Stock Comparison
DTXMF vs SEMHF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, SEMHF has a market cap of 45.5B. Regarding current trading prices, DTXMF is priced at $0.10, while SEMHF trades at $40.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas SEMHF's P/E ratio is 18.48. In terms of profitability, DTXMF's ROE is -0.74%, compared to SEMHF's ROE of +0.11%. Regarding short-term risk, DTXMF is more volatile compared to SEMHF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check SEMHF's competition here
DTXMF vs RSMDF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, RSMDF has a market cap of 43.3B. Regarding current trading prices, DTXMF is priced at $0.10, while RSMDF trades at $17.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas RSMDF's P/E ratio is 28.67. In terms of profitability, DTXMF's ROE is -0.74%, compared to RSMDF's ROE of +0.24%. Regarding short-term risk, DTXMF is more volatile compared to RSMDF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check RSMDF's competition here
DTXMF vs FUJIY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, FUJIY has a market cap of 25.4B. Regarding current trading prices, DTXMF is priced at $0.10, while FUJIY trades at $10.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas FUJIY's P/E ratio is 15.04. In terms of profitability, DTXMF's ROE is -0.74%, compared to FUJIY's ROE of +0.08%. Regarding short-term risk, DTXMF is more volatile compared to FUJIY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check FUJIY's competition here
DTXMF vs RYLPF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, RYLPF has a market cap of 24.2B. Regarding current trading prices, DTXMF is priced at $0.10, while RYLPF trades at $25.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas RYLPF's P/E ratio is 21.93. In terms of profitability, DTXMF's ROE is -0.74%, compared to RYLPF's ROE of +0.09%. Regarding short-term risk, DTXMF is more volatile compared to RYLPF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check RYLPF's competition here
DTXMF vs FUJIF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, FUJIF has a market cap of 23.9B. Regarding current trading prices, DTXMF is priced at $0.10, while FUJIF trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas FUJIF's P/E ratio is 14.18. In terms of profitability, DTXMF's ROE is -0.74%, compared to FUJIF's ROE of +0.10%. Regarding short-term risk, DTXMF is more volatile compared to FUJIF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check FUJIF's competition here
DTXMF vs SMMNY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, SMMNY has a market cap of 22.3B. Regarding current trading prices, DTXMF is priced at $0.10, while SMMNY trades at $19.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas SMMNY's P/E ratio is 18.15. In terms of profitability, DTXMF's ROE is -0.74%, compared to SMMNY's ROE of +0.11%. Regarding short-term risk, DTXMF is more volatile compared to SMMNY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check SMMNY's competition here
DTXMF vs SONVF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, SONVF has a market cap of 15.9B. Regarding current trading prices, DTXMF is priced at $0.10, while SONVF trades at $275.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas SONVF's P/E ratio is 23.43. In terms of profitability, DTXMF's ROE is -0.74%, compared to SONVF's ROE of +0.21%. Regarding short-term risk, DTXMF is more volatile compared to SONVF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check SONVF's competition here
DTXMF vs SONVY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, SONVY has a market cap of 15.5B. Regarding current trading prices, DTXMF is priced at $0.10, while SONVY trades at $52.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas SONVY's P/E ratio is 22.79. In terms of profitability, DTXMF's ROE is -0.74%, compared to SONVY's ROE of +0.22%. Regarding short-term risk, DTXMF is more volatile compared to SONVY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check SONVY's competition here
DTXMF vs CLPBY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CLPBY has a market cap of 13.5B. Regarding current trading prices, DTXMF is priced at $0.10, while CLPBY trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CLPBY's P/E ratio is 40.07. In terms of profitability, DTXMF's ROE is -0.74%, compared to CLPBY's ROE of +0.14%. Regarding short-term risk, DTXMF is more volatile compared to CLPBY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CLPBY's competition here
DTXMF vs CLPBF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CLPBF has a market cap of 13.5B. Regarding current trading prices, DTXMF is priced at $0.10, while CLPBF trades at $60.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CLPBF's P/E ratio is 44.94. In terms of profitability, DTXMF's ROE is -0.74%, compared to CLPBF's ROE of +0.14%. Regarding short-term risk, DTXMF is more volatile compared to CLPBF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CLPBF's competition here
DTXMF vs SNNUF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, SNNUF has a market cap of 12.7B. Regarding current trading prices, DTXMF is priced at $0.10, while SNNUF trades at $14.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas SNNUF's P/E ratio is 20.76. In terms of profitability, DTXMF's ROE is -0.74%, compared to SNNUF's ROE of +0.12%. Regarding short-term risk, DTXMF is more volatile compared to SNNUF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check SNNUF's competition here
DTXMF vs OCPNF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, OCPNF has a market cap of 12.3B. Regarding current trading prices, DTXMF is priced at $0.10, while OCPNF trades at $11.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas OCPNF's P/E ratio is 29.42. In terms of profitability, DTXMF's ROE is -0.74%, compared to OCPNF's ROE of +0.09%. Regarding short-term risk, DTXMF is more volatile compared to OCPNF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check OCPNF's competition here
DTXMF vs WILYY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, WILYY has a market cap of 8.3B. Regarding current trading prices, DTXMF is priced at $0.10, while WILYY trades at $19.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas WILYY's P/E ratio is 22.59. In terms of profitability, DTXMF's ROE is -0.74%, compared to WILYY's ROE of +0.16%. Regarding short-term risk, DTXMF is more volatile compared to WILYY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check WILYY's competition here
DTXMF vs WILLF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, WILLF has a market cap of 7.5B. Regarding current trading prices, DTXMF is priced at $0.10, while WILLF trades at $35.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas WILLF's P/E ratio is 20.37. In terms of profitability, DTXMF's ROE is -0.74%, compared to WILLF's ROE of +0.16%. Regarding short-term risk, DTXMF is more volatile compared to WILLF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check WILLF's competition here
DTXMF vs GNGBY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, GNGBY has a market cap of 5.4B. Regarding current trading prices, DTXMF is priced at $0.10, while GNGBY trades at $19.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas GNGBY's P/E ratio is 21.33. In terms of profitability, DTXMF's ROE is -0.74%, compared to GNGBY's ROE of +0.08%. Regarding short-term risk, DTXMF is more volatile compared to GNGBY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check GNGBY's competition here
DTXMF vs GNGBF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, GNGBF has a market cap of 5.1B. Regarding current trading prices, DTXMF is priced at $0.10, while GNGBF trades at $20.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas GNGBF's P/E ratio is 21.56. In terms of profitability, DTXMF's ROE is -0.74%, compared to GNGBF's ROE of +0.08%. Regarding short-term risk, DTXMF is more volatile compared to GNGBF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check GNGBF's competition here
DTXMF vs YPHDF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, YPHDF has a market cap of 4.8B. Regarding current trading prices, DTXMF is priced at $0.10, while YPHDF trades at $354.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas YPHDF's P/E ratio is 17.78. In terms of profitability, DTXMF's ROE is -0.74%, compared to YPHDF's ROE of +0.38%. Regarding short-term risk, DTXMF is more volatile compared to YPHDF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check YPHDF's competition here
DTXMF vs CHEOF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CHEOF has a market cap of 4.7B. Regarding current trading prices, DTXMF is priced at $0.10, while CHEOF trades at $72.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CHEOF's P/E ratio is 19.29. In terms of profitability, DTXMF's ROE is -0.74%, compared to CHEOF's ROE of +0.18%. Regarding short-term risk, DTXMF is more volatile compared to CHEOF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CHEOF's competition here
DTXMF vs CHEOY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CHEOY has a market cap of 4.7B. Regarding current trading prices, DTXMF is priced at $0.10, while CHEOY trades at $36.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CHEOY's P/E ratio is 19.26. In terms of profitability, DTXMF's ROE is -0.74%, compared to CHEOY's ROE of +0.18%. Regarding short-term risk, DTXMF is more volatile compared to CHEOY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CHEOY's competition here
DTXMF vs NHNKY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, NHNKY has a market cap of 2.8B. Regarding current trading prices, DTXMF is priced at $0.10, while NHNKY trades at $8.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas NHNKY's P/E ratio is 15.71. In terms of profitability, DTXMF's ROE is -0.74%, compared to NHNKY's ROE of +0.08%. Regarding short-term risk, DTXMF is more volatile compared to NHNKY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check NHNKY's competition here
DTXMF vs AMFPF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, AMFPF has a market cap of 2.6B. Regarding current trading prices, DTXMF is priced at $0.10, while AMFPF trades at $12.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas AMFPF's P/E ratio is 33.36. In terms of profitability, DTXMF's ROE is -0.74%, compared to AMFPF's ROE of +0.07%. Regarding short-term risk, DTXMF is more volatile compared to AMFPF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check AMFPF's competition here
DTXMF vs AMBBY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, AMBBY has a market cap of 2.6B. Regarding current trading prices, DTXMF is priced at $0.10, while AMBBY trades at $10.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas AMBBY's P/E ratio is 35.64. In terms of profitability, DTXMF's ROE is -0.74%, compared to AMBBY's ROE of +0.08%. Regarding short-term risk, DTXMF is more volatile compared to AMBBY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check AMBBY's competition here
DTXMF vs AMBFF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, AMBFF has a market cap of 2.6B. Regarding current trading prices, DTXMF is priced at $0.10, while AMBFF trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas AMBFF's P/E ratio is 35.36. In terms of profitability, DTXMF's ROE is -0.74%, compared to AMBFF's ROE of +0.08%. Regarding short-term risk, DTXMF is more volatile compared to AMBFF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check AMBFF's competition here
DTXMF vs GNNDY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, GNNDY has a market cap of 2.2B. Regarding current trading prices, DTXMF is priced at $0.10, while GNNDY trades at $45.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas GNNDY's P/E ratio is 53.85. In terms of profitability, DTXMF's ROE is -0.74%, compared to GNNDY's ROE of -0.04%. Regarding short-term risk, DTXMF is more volatile compared to GNNDY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check GNNDY's competition here
DTXMF vs OSSFF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, OSSFF has a market cap of 2.2B. Regarding current trading prices, DTXMF is priced at $0.10, while OSSFF trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas OSSFF's P/E ratio is 25.55. In terms of profitability, DTXMF's ROE is -0.74%, compared to OSSFF's ROE of +0.10%. Regarding short-term risk, DTXMF is more volatile compared to OSSFF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check OSSFF's competition here
DTXMF vs DRWKF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, DRWKF has a market cap of 2.1B. Regarding current trading prices, DTXMF is priced at $0.10, while DRWKF trades at $111.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas DRWKF's P/E ratio is 11.79. In terms of profitability, DTXMF's ROE is -0.74%, compared to DRWKF's ROE of +0.10%. Regarding short-term risk, DTXMF is more volatile compared to DRWKF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check DRWKF's competition here
DTXMF vs GGNDF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, GGNDF has a market cap of 2.1B. Regarding current trading prices, DTXMF is priced at $0.10, while GGNDF trades at $14.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas GGNDF's P/E ratio is 51.25. In terms of profitability, DTXMF's ROE is -0.74%, compared to GGNDF's ROE of -0.04%. Regarding short-term risk, DTXMF is more volatile compared to GGNDF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check GGNDF's competition here
DTXMF vs MCRPF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, MCRPF has a market cap of 1.9B. Regarding current trading prices, DTXMF is priced at $0.10, while MCRPF trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas MCRPF's P/E ratio is -10.77. In terms of profitability, DTXMF's ROE is -0.74%, compared to MCRPF's ROE of +0.06%. Regarding short-term risk, DTXMF is more volatile compared to MCRPF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check MCRPF's competition here
DTXMF vs OSSUY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, OSSUY has a market cap of 1.8B. Regarding current trading prices, DTXMF is priced at $0.10, while OSSUY trades at $3.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas OSSUY's P/E ratio is 20.65. In terms of profitability, DTXMF's ROE is -0.74%, compared to OSSUY's ROE of +0.10%. Regarding short-term risk, DTXMF is more volatile compared to OSSUY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check OSSUY's competition here
DTXMF vs DWRKF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, DWRKF has a market cap of 1.8B. Regarding current trading prices, DTXMF is priced at $0.10, while DWRKF trades at $543.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas DWRKF's P/E ratio is 75.94. In terms of profitability, DTXMF's ROE is -0.74%, compared to DWRKF's ROE of N/A. Regarding short-term risk, DTXMF is more volatile compared to DWRKF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check DWRKF's competition here
DTXMF vs NHNKF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, NHNKF has a market cap of 1.7B. Regarding current trading prices, DTXMF is priced at $0.10, while NHNKF trades at $15.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas NHNKF's P/E ratio is 30.28. In terms of profitability, DTXMF's ROE is -0.74%, compared to NHNKF's ROE of +0.08%. Regarding short-term risk, DTXMF is more volatile compared to NHNKF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check NHNKF's competition here
DTXMF vs MEDGF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, MEDGF has a market cap of 1.7B. Regarding current trading prices, DTXMF is priced at $0.10, while MEDGF trades at $83.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas MEDGF's P/E ratio is 33.30. In terms of profitability, DTXMF's ROE is -0.74%, compared to MEDGF's ROE of +0.22%. Regarding short-term risk, DTXMF is more volatile compared to MEDGF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check MEDGF's competition here
DTXMF vs BOEUF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, BOEUF has a market cap of 1.6B. Regarding current trading prices, DTXMF is priced at $0.10, while BOEUF trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas BOEUF's P/E ratio is 83.30. In terms of profitability, DTXMF's ROE is -0.74%, compared to BOEUF's ROE of +0.22%. Regarding short-term risk, DTXMF is more volatile compared to BOEUF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check BOEUF's competition here
DTXMF vs VTRLY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, VTRLY has a market cap of 1.5B. Regarding current trading prices, DTXMF is priced at $0.10, while VTRLY trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas VTRLY's P/E ratio is -2.76. In terms of profitability, DTXMF's ROE is -0.74%, compared to VTRLY's ROE of -0.47%. Regarding short-term risk, DTXMF is more volatile compared to VTRLY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check VTRLY's competition here
DTXMF vs FDMDF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, FDMDF has a market cap of 1.5B. Regarding current trading prices, DTXMF is priced at $0.10, while FDMDF trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas FDMDF's P/E ratio is -8.62. In terms of profitability, DTXMF's ROE is -0.74%, compared to FDMDF's ROE of -9.21%. Regarding short-term risk, DTXMF is more volatile compared to FDMDF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check FDMDF's competition here
DTXMF vs MDRSF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, MDRSF has a market cap of 1.4B. Regarding current trading prices, DTXMF is priced at $0.10, while MDRSF trades at $115.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas MDRSF's P/E ratio is 135.29. In terms of profitability, DTXMF's ROE is -0.74%, compared to MDRSF's ROE of +0.03%. Regarding short-term risk, DTXMF is more volatile compared to MDRSF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check MDRSF's competition here
DTXMF vs DGWPF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, DGWPF has a market cap of 1.4B. Regarding current trading prices, DTXMF is priced at $0.10, while DGWPF trades at $83.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas DGWPF's P/E ratio is 7.62. In terms of profitability, DTXMF's ROE is -0.74%, compared to DGWPF's ROE of +0.10%. Regarding short-term risk, DTXMF is more volatile compared to DGWPF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check DGWPF's competition here
DTXMF vs LFTSF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, LFTSF has a market cap of 858.1M. Regarding current trading prices, DTXMF is priced at $0.10, while LFTSF trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas LFTSF's P/E ratio is 19.50. In terms of profitability, DTXMF's ROE is -0.74%, compared to LFTSF's ROE of +0.02%. Regarding short-term risk, DTXMF is more volatile compared to LFTSF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check LFTSF's competition here
DTXMF vs ELEAF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, ELEAF has a market cap of 759.8M. Regarding current trading prices, DTXMF is priced at $0.10, while ELEAF trades at $15.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas ELEAF's P/E ratio is 12.31. In terms of profitability, DTXMF's ROE is -0.74%, compared to ELEAF's ROE of +0.17%. Regarding short-term risk, DTXMF is more volatile compared to ELEAF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check ELEAF's competition here
DTXMF vs XVIPF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, XVIPF has a market cap of 603.2M. Regarding current trading prices, DTXMF is priced at $0.10, while XVIPF trades at $29.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas XVIPF's P/E ratio is 76.60. In terms of profitability, DTXMF's ROE is -0.74%, compared to XVIPF's ROE of +0.03%. Regarding short-term risk, DTXMF is more volatile compared to XVIPF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check XVIPF's competition here
DTXMF vs BRSYF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, BRSYF has a market cap of 543.2M. Regarding current trading prices, DTXMF is priced at $0.10, while BRSYF trades at $16.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas BRSYF's P/E ratio is 61.59. In terms of profitability, DTXMF's ROE is -0.74%, compared to BRSYF's ROE of +0.12%. Regarding short-term risk, DTXMF is more volatile compared to BRSYF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check BRSYF's competition here
DTXMF vs IOBCF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, IOBCF has a market cap of 501.5M. Regarding current trading prices, DTXMF is priced at $0.10, while IOBCF trades at $18.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas IOBCF's P/E ratio is 34.90. In terms of profitability, DTXMF's ROE is -0.74%, compared to IOBCF's ROE of +0.10%. Regarding short-term risk, DTXMF is more volatile compared to IOBCF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check IOBCF's competition here
DTXMF vs AVMR Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, AVMR has a market cap of 494.2M. Regarding current trading prices, DTXMF is priced at $0.10, while AVMR trades at $9.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas AVMR's P/E ratio is -18.34. In terms of profitability, DTXMF's ROE is -0.74%, compared to AVMR's ROE of -0.23%. Regarding short-term risk, DTXMF is more volatile compared to AVMR. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check AVMR's competition here
DTXMF vs CALZF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CALZF has a market cap of 414.5M. Regarding current trading prices, DTXMF is priced at $0.10, while CALZF trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CALZF's P/E ratio is 60.00. In terms of profitability, DTXMF's ROE is -0.74%, compared to CALZF's ROE of +0.12%. Regarding short-term risk, DTXMF is more volatile compared to CALZF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CALZF's competition here
DTXMF vs HYBT Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, HYBT has a market cap of 361.4M. Regarding current trading prices, DTXMF is priced at $0.10, while HYBT trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas HYBT's P/E ratio is N/A. In terms of profitability, DTXMF's ROE is -0.74%, compared to HYBT's ROE of +0.02%. Regarding short-term risk, DTXMF is more volatile compared to HYBT. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check HYBT's competition here
DTXMF vs CYBQY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CYBQY has a market cap of 333.5M. Regarding current trading prices, DTXMF is priced at $0.10, while CYBQY trades at $1.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CYBQY's P/E ratio is -187.00. In terms of profitability, DTXMF's ROE is -0.74%, compared to CYBQY's ROE of +0.01%. Regarding short-term risk, DTXMF is more volatile compared to CYBQY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CYBQY's competition here
DTXMF vs CLVSF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CLVSF has a market cap of 321.8M. Regarding current trading prices, DTXMF is priced at $0.10, while CLVSF trades at $13.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CLVSF's P/E ratio is 22.48. In terms of profitability, DTXMF's ROE is -0.74%, compared to CLVSF's ROE of +0.15%. Regarding short-term risk, DTXMF is more volatile compared to CLVSF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CLVSF's competition here
DTXMF vs CSSPF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CSSPF has a market cap of 273.5M. Regarding current trading prices, DTXMF is priced at $0.10, while CSSPF trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CSSPF's P/E ratio is 32.50. In terms of profitability, DTXMF's ROE is -0.74%, compared to CSSPF's ROE of +0.10%. Regarding short-term risk, DTXMF is more volatile compared to CSSPF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CSSPF's competition here
DTXMF vs DMTRF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, DMTRF has a market cap of 270.5M. Regarding current trading prices, DTXMF is priced at $0.10, while DMTRF trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas DMTRF's P/E ratio is -112.50. In terms of profitability, DTXMF's ROE is -0.74%, compared to DMTRF's ROE of +0.36%. Regarding short-term risk, DTXMF is more volatile compared to DMTRF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check DMTRF's competition here
DTXMF vs CYBQF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CYBQF has a market cap of 248.8M. Regarding current trading prices, DTXMF is priced at $0.10, while CYBQF trades at $1.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CYBQF's P/E ratio is -186.50. In terms of profitability, DTXMF's ROE is -0.74%, compared to CYBQF's ROE of +0.00%. Regarding short-term risk, DTXMF is more volatile compared to CYBQF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CYBQF's competition here
DTXMF vs EBRCZ Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, EBRCZ has a market cap of 246.1M. Regarding current trading prices, DTXMF is priced at $0.10, while EBRCZ trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas EBRCZ's P/E ratio is -1.50. In terms of profitability, DTXMF's ROE is -0.74%, compared to EBRCZ's ROE of -1.80%. Regarding short-term risk, DTXMF is more volatile compared to EBRCZ. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check EBRCZ's competition here
DTXMF vs HTLZF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, HTLZF has a market cap of 245.1M. Regarding current trading prices, DTXMF is priced at $0.10, while HTLZF trades at $1.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas HTLZF's P/E ratio is -159.01. In terms of profitability, DTXMF's ROE is -0.74%, compared to HTLZF's ROE of -0.01%. Regarding short-term risk, DTXMF is more volatile compared to HTLZF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check HTLZF's competition here
DTXMF vs IMPZY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, IMPZY has a market cap of 229.3M. Regarding current trading prices, DTXMF is priced at $0.10, while IMPZY trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas IMPZY's P/E ratio is -1.60. In terms of profitability, DTXMF's ROE is -0.74%, compared to IMPZY's ROE of +8.77%. Regarding short-term risk, DTXMF is more volatile compared to IMPZY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check IMPZY's competition here
DTXMF vs XVIPY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, XVIPY has a market cap of 206M. Regarding current trading prices, DTXMF is priced at $0.10, while XVIPY trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas XVIPY's P/E ratio is N/A. In terms of profitability, DTXMF's ROE is -0.74%, compared to XVIPY's ROE of +0.01%. Regarding short-term risk, DTXMF is more volatile compared to XVIPY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check XVIPY's competition here
DTXMF vs VMTHF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, VMTHF has a market cap of 186.1M. Regarding current trading prices, DTXMF is priced at $0.10, while VMTHF trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas VMTHF's P/E ratio is -3.01. In terms of profitability, DTXMF's ROE is -0.74%, compared to VMTHF's ROE of -0.21%. Regarding short-term risk, DTXMF is more volatile compared to VMTHF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check VMTHF's competition here
DTXMF vs EKDHF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, EKDHF has a market cap of 167.9M. Regarding current trading prices, DTXMF is priced at $0.10, while EKDHF trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas EKDHF's P/E ratio is 39.00. In terms of profitability, DTXMF's ROE is -0.74%, compared to EKDHF's ROE of +0.03%. Regarding short-term risk, DTXMF is more volatile compared to EKDHF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check EKDHF's competition here
DTXMF vs EAPIF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, EAPIF has a market cap of 162.8M. Regarding current trading prices, DTXMF is priced at $0.10, while EAPIF trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas EAPIF's P/E ratio is -0.66. In terms of profitability, DTXMF's ROE is -0.74%, compared to EAPIF's ROE of -0.24%. Regarding short-term risk, DTXMF is more volatile compared to EAPIF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check EAPIF's competition here
DTXMF vs BRNHF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, BRNHF has a market cap of 161.7M. Regarding current trading prices, DTXMF is priced at $0.10, while BRNHF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas BRNHF's P/E ratio is -5.12. In terms of profitability, DTXMF's ROE is -0.74%, compared to BRNHF's ROE of -0.09%. Regarding short-term risk, DTXMF is more volatile compared to BRNHF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check BRNHF's competition here
DTXMF vs JMDMF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, JMDMF has a market cap of 156.4M. Regarding current trading prices, DTXMF is priced at $0.10, while JMDMF trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas JMDMF's P/E ratio is 83.33. In terms of profitability, DTXMF's ROE is -0.74%, compared to JMDMF's ROE of N/A. Regarding short-term risk, DTXMF is more volatile compared to JMDMF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check JMDMF's competition here
DTXMF vs BCCOY Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, BCCOY has a market cap of 143M. Regarding current trading prices, DTXMF is priced at $0.10, while BCCOY trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas BCCOY's P/E ratio is -0.90. In terms of profitability, DTXMF's ROE is -0.74%, compared to BCCOY's ROE of -0.51%. Regarding short-term risk, DTXMF is more volatile compared to BCCOY. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check BCCOY's competition here
DTXMF vs CLLKF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CLLKF has a market cap of 136.8M. Regarding current trading prices, DTXMF is priced at $0.10, while CLLKF trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CLLKF's P/E ratio is -0.88. In terms of profitability, DTXMF's ROE is -0.74%, compared to CLLKF's ROE of -0.52%. Regarding short-term risk, DTXMF is more volatile compared to CLLKF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CLLKF's competition here
DTXMF vs AMEUF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, AMEUF has a market cap of 120.5M. Regarding current trading prices, DTXMF is priced at $0.10, while AMEUF trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas AMEUF's P/E ratio is -1.75. In terms of profitability, DTXMF's ROE is -0.74%, compared to AMEUF's ROE of -1.90%. Regarding short-term risk, DTXMF is more volatile compared to AMEUF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check AMEUF's competition here
DTXMF vs PXMBF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, PXMBF has a market cap of 119.9M. Regarding current trading prices, DTXMF is priced at $0.10, while PXMBF trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas PXMBF's P/E ratio is 23.33. In terms of profitability, DTXMF's ROE is -0.74%, compared to PXMBF's ROE of -0.03%. Regarding short-term risk, DTXMF is more volatile compared to PXMBF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check PXMBF's competition here
DTXMF vs AVHHL Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, AVHHL has a market cap of 105M. Regarding current trading prices, DTXMF is priced at $0.10, while AVHHL trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas AVHHL's P/E ratio is -2.73. In terms of profitability, DTXMF's ROE is -0.74%, compared to AVHHL's ROE of +3.05%. Regarding short-term risk, DTXMF is more volatile compared to AVHHL. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check AVHHL's competition here
DTXMF vs SOMNF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, SOMNF has a market cap of 98.6M. Regarding current trading prices, DTXMF is priced at $0.10, while SOMNF trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas SOMNF's P/E ratio is -45.00. In terms of profitability, DTXMF's ROE is -0.74%, compared to SOMNF's ROE of -0.05%. Regarding short-term risk, DTXMF is more volatile compared to SOMNF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check SOMNF's competition here
DTXMF vs RSHUF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, RSHUF has a market cap of 91.5M. Regarding current trading prices, DTXMF is priced at $0.10, while RSHUF trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas RSHUF's P/E ratio is -5.81. In terms of profitability, DTXMF's ROE is -0.74%, compared to RSHUF's ROE of -4.12%. Regarding short-term risk, DTXMF is more volatile compared to RSHUF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check RSHUF's competition here
DTXMF vs CKMTF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, CKMTF has a market cap of 85.2M. Regarding current trading prices, DTXMF is priced at $0.10, while CKMTF trades at $12.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas CKMTF's P/E ratio is -3.32. In terms of profitability, DTXMF's ROE is -0.74%, compared to CKMTF's ROE of +2.58%. Regarding short-term risk, DTXMF is more volatile compared to CKMTF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check CKMTF's competition here
DTXMF vs SNZZF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, SNZZF has a market cap of 78.9M. Regarding current trading prices, DTXMF is priced at $0.10, while SNZZF trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas SNZZF's P/E ratio is -5.58. In terms of profitability, DTXMF's ROE is -0.74%, compared to SNZZF's ROE of -0.38%. Regarding short-term risk, DTXMF is more volatile compared to SNZZF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check SNZZF's competition here
DTXMF vs BLOZF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, BLOZF has a market cap of 56.4M. Regarding current trading prices, DTXMF is priced at $0.10, while BLOZF trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas BLOZF's P/E ratio is -11.50. In terms of profitability, DTXMF's ROE is -0.74%, compared to BLOZF's ROE of -3.03%. Regarding short-term risk, DTXMF is more volatile compared to BLOZF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check BLOZF's competition here
DTXMF vs TLTFF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, TLTFF has a market cap of 50.4M. Regarding current trading prices, DTXMF is priced at $0.10, while TLTFF trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas TLTFF's P/E ratio is -17.05. In terms of profitability, DTXMF's ROE is -0.74%, compared to TLTFF's ROE of -2.42%. Regarding short-term risk, DTXMF is more volatile compared to TLTFF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check TLTFF's competition here
DTXMF vs NVYTF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, NVYTF has a market cap of 34.8M. Regarding current trading prices, DTXMF is priced at $0.10, while NVYTF trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas NVYTF's P/E ratio is -0.86. In terms of profitability, DTXMF's ROE is -0.74%, compared to NVYTF's ROE of -1.22%. Regarding short-term risk, DTXMF is more volatile compared to NVYTF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check NVYTF's competition here
DTXMF vs RDGL Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, RDGL has a market cap of 33.1M. Regarding current trading prices, DTXMF is priced at $0.10, while RDGL trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas RDGL's P/E ratio is -6.71. In terms of profitability, DTXMF's ROE is -0.74%, compared to RDGL's ROE of -1.48%. Regarding short-term risk, DTXMF is more volatile compared to RDGL. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check RDGL's competition here
DTXMF vs ACIXF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, ACIXF has a market cap of 31.5M. Regarding current trading prices, DTXMF is priced at $0.10, while ACIXF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas ACIXF's P/E ratio is -2.80. In terms of profitability, DTXMF's ROE is -0.74%, compared to ACIXF's ROE of -1.06%. Regarding short-term risk, DTXMF is more volatile compared to ACIXF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check ACIXF's competition here
DTXMF vs POSC Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, POSC has a market cap of 27.4M. Regarding current trading prices, DTXMF is priced at $0.10, while POSC trades at $1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas POSC's P/E ratio is -5.82. In terms of profitability, DTXMF's ROE is -0.74%, compared to POSC's ROE of -7.67%. Regarding short-term risk, DTXMF is more volatile compared to POSC. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check POSC's competition here
DTXMF vs MKEAF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, MKEAF has a market cap of 25.9M. Regarding current trading prices, DTXMF is priced at $0.10, while MKEAF trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas MKEAF's P/E ratio is -4.11. In terms of profitability, DTXMF's ROE is -0.74%, compared to MKEAF's ROE of +0.50%. Regarding short-term risk, DTXMF is more volatile compared to MKEAF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check MKEAF's competition here
DTXMF vs TCLIF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, TCLIF has a market cap of 25.1M. Regarding current trading prices, DTXMF is priced at $0.10, while TCLIF trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas TCLIF's P/E ratio is -4.84. In terms of profitability, DTXMF's ROE is -0.74%, compared to TCLIF's ROE of +2.39%. Regarding short-term risk, DTXMF is less volatile compared to TCLIF. This indicates potentially lower risk in terms of short-term price fluctuations for DTXMF.Check TCLIF's competition here
DTXMF vs KBBTF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, KBBTF has a market cap of 24.1M. Regarding current trading prices, DTXMF is priced at $0.10, while KBBTF trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas KBBTF's P/E ratio is -2.30. In terms of profitability, DTXMF's ROE is -0.74%, compared to KBBTF's ROE of N/A. Regarding short-term risk, DTXMF is more volatile compared to KBBTF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check KBBTF's competition here
DTXMF vs PYNKF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, PYNKF has a market cap of 22.1M. Regarding current trading prices, DTXMF is priced at $0.10, while PYNKF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas PYNKF's P/E ratio is 3.79. In terms of profitability, DTXMF's ROE is -0.74%, compared to PYNKF's ROE of -3.36%. Regarding short-term risk, DTXMF is more volatile compared to PYNKF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check PYNKF's competition here
DTXMF vs EMITF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, EMITF has a market cap of 21.3M. Regarding current trading prices, DTXMF is priced at $0.10, while EMITF trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas EMITF's P/E ratio is -7.62. In terms of profitability, DTXMF's ROE is -0.74%, compared to EMITF's ROE of -0.07%. Regarding short-term risk, DTXMF is more volatile compared to EMITF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check EMITF's competition here
DTXMF vs DIZTF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, DIZTF has a market cap of 18M. Regarding current trading prices, DTXMF is priced at $0.10, while DIZTF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas DIZTF's P/E ratio is -11.16. In terms of profitability, DTXMF's ROE is -0.74%, compared to DIZTF's ROE of -0.52%. Regarding short-term risk, DTXMF is more volatile compared to DIZTF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check DIZTF's competition here
DTXMF vs VPTDF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, VPTDF has a market cap of 15.9M. Regarding current trading prices, DTXMF is priced at $0.10, while VPTDF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas VPTDF's P/E ratio is -8.47. In terms of profitability, DTXMF's ROE is -0.74%, compared to VPTDF's ROE of +0.78%. Regarding short-term risk, DTXMF is more volatile compared to VPTDF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check VPTDF's competition here
DTXMF vs GTHP Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, GTHP has a market cap of 15.7M. Regarding current trading prices, DTXMF is priced at $0.10, while GTHP trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas GTHP's P/E ratio is -5.11. In terms of profitability, DTXMF's ROE is -0.74%, compared to GTHP's ROE of +0.71%. Regarding short-term risk, DTXMF is more volatile compared to GTHP. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check GTHP's competition here
DTXMF vs MDXHF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, MDXHF has a market cap of 14.4M. Regarding current trading prices, DTXMF is priced at $0.10, while MDXHF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas MDXHF's P/E ratio is -4.40. In terms of profitability, DTXMF's ROE is -0.74%, compared to MDXHF's ROE of +0.62%. Regarding short-term risk, DTXMF is more volatile compared to MDXHF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check MDXHF's competition here
DTXMF vs TMDIF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, TMDIF has a market cap of 13.9M. Regarding current trading prices, DTXMF is priced at $0.10, while TMDIF trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas TMDIF's P/E ratio is -0.65. In terms of profitability, DTXMF's ROE is -0.74%, compared to TMDIF's ROE of +8.70%. Regarding short-term risk, DTXMF is more volatile compared to TMDIF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check TMDIF's competition here
DTXMF vs ASAPF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, ASAPF has a market cap of 13.7M. Regarding current trading prices, DTXMF is priced at $0.10, while ASAPF trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas ASAPF's P/E ratio is -17.50. In terms of profitability, DTXMF's ROE is -0.74%, compared to ASAPF's ROE of -0.15%. Regarding short-term risk, DTXMF is more volatile compared to ASAPF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check ASAPF's competition here
DTXMF vs IPDQF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, IPDQF has a market cap of 12.1M. Regarding current trading prices, DTXMF is priced at $0.10, while IPDQF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas IPDQF's P/E ratio is -0.59. In terms of profitability, DTXMF's ROE is -0.74%, compared to IPDQF's ROE of -1.65%. Regarding short-term risk, DTXMF is more volatile compared to IPDQF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check IPDQF's competition here
DTXMF vs ATBPF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, ATBPF has a market cap of 11.4M. Regarding current trading prices, DTXMF is priced at $0.10, while ATBPF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas ATBPF's P/E ratio is -0.86. In terms of profitability, DTXMF's ROE is -0.74%, compared to ATBPF's ROE of -0.40%. Regarding short-term risk, DTXMF is more volatile compared to ATBPF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check ATBPF's competition here
DTXMF vs ALRTF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, ALRTF has a market cap of 11.4M. Regarding current trading prices, DTXMF is priced at $0.10, while ALRTF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas ALRTF's P/E ratio is -0.44. In terms of profitability, DTXMF's ROE is -0.74%, compared to ALRTF's ROE of +0.52%. Regarding short-term risk, DTXMF is more volatile compared to ALRTF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check ALRTF's competition here
DTXMF vs LXXGF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, LXXGF has a market cap of 11.3M. Regarding current trading prices, DTXMF is priced at $0.10, while LXXGF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas LXXGF's P/E ratio is -0.85. In terms of profitability, DTXMF's ROE is -0.74%, compared to LXXGF's ROE of -1.23%. Regarding short-term risk, DTXMF is more volatile compared to LXXGF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check LXXGF's competition here
DTXMF vs PLLWF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, PLLWF has a market cap of 8M. Regarding current trading prices, DTXMF is priced at $0.10, while PLLWF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas PLLWF's P/E ratio is -0.66. In terms of profitability, DTXMF's ROE is -0.74%, compared to PLLWF's ROE of -0.99%. Regarding short-term risk, DTXMF is more volatile compared to PLLWF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check PLLWF's competition here
DTXMF vs BIEL Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, BIEL has a market cap of 7.2M. Regarding current trading prices, DTXMF is priced at $0.10, while BIEL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas BIEL's P/E ratio is N/A. In terms of profitability, DTXMF's ROE is -0.74%, compared to BIEL's ROE of +0.05%. Regarding short-term risk, DTXMF is more volatile compared to BIEL. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check BIEL's competition here
DTXMF vs QLIS Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, QLIS has a market cap of 5.5M. Regarding current trading prices, DTXMF is priced at $0.10, while QLIS trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas QLIS's P/E ratio is 2.22. In terms of profitability, DTXMF's ROE is -0.74%, compared to QLIS's ROE of -0.15%. Regarding short-term risk, DTXMF is more volatile compared to QLIS. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check QLIS's competition here
DTXMF vs RHNMF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, RHNMF has a market cap of 5.4M. Regarding current trading prices, DTXMF is priced at $0.10, while RHNMF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas RHNMF's P/E ratio is -0.95. In terms of profitability, DTXMF's ROE is -0.74%, compared to RHNMF's ROE of +15.91%. Regarding short-term risk, DTXMF is more volatile compared to RHNMF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check RHNMF's competition here
DTXMF vs PMEDF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, PMEDF has a market cap of 5.2M. Regarding current trading prices, DTXMF is priced at $0.10, while PMEDF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas PMEDF's P/E ratio is -2.52. In terms of profitability, DTXMF's ROE is -0.74%, compared to PMEDF's ROE of +1.24%. Regarding short-term risk, DTXMF is more volatile compared to PMEDF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check PMEDF's competition here
DTXMF vs ADMT Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, ADMT has a market cap of 4.7M. Regarding current trading prices, DTXMF is priced at $0.10, while ADMT trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas ADMT's P/E ratio is -6.90. In terms of profitability, DTXMF's ROE is -0.74%, compared to ADMT's ROE of -0.01%. Regarding short-term risk, DTXMF is more volatile compared to ADMT. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check ADMT's competition here
DTXMF vs USAQ Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, USAQ has a market cap of 4.1M. Regarding current trading prices, DTXMF is priced at $0.10, while USAQ trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas USAQ's P/E ratio is 11.17. In terms of profitability, DTXMF's ROE is -0.74%, compared to USAQ's ROE of +0.92%. Regarding short-term risk, DTXMF is more volatile compared to USAQ. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check USAQ's competition here
DTXMF vs RMSL Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, RMSL has a market cap of 3.7M. Regarding current trading prices, DTXMF is priced at $0.10, while RMSL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas RMSL's P/E ratio is 0.22. In terms of profitability, DTXMF's ROE is -0.74%, compared to RMSL's ROE of -17961324.55%. Regarding short-term risk, DTXMF is more volatile compared to RMSL. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check RMSL's competition here
DTXMF vs VANIW Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, VANIW has a market cap of 3.4M. Regarding current trading prices, DTXMF is priced at $0.10, while VANIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas VANIW's P/E ratio is N/A. In terms of profitability, DTXMF's ROE is -0.74%, compared to VANIW's ROE of -2.64%. Regarding short-term risk, DTXMF is more volatile compared to VANIW. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check VANIW's competition here
DTXMF vs NGMDF Comparison June 2026
DTXMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DTXMF stands at 180.6M. In comparison, NGMDF has a market cap of 3.3M. Regarding current trading prices, DTXMF is priced at $0.10, while NGMDF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DTXMF currently has a P/E ratio of -9.52, whereas NGMDF's P/E ratio is -0.49. In terms of profitability, DTXMF's ROE is -0.74%, compared to NGMDF's ROE of +0.94%. Regarding short-term risk, DTXMF is more volatile compared to NGMDF. This indicates potentially higher risk in terms of short-term price fluctuations for DTXMF.Check NGMDF's competition here